Xiulan Zheng

Xiulan Zheng

Auto-generated profile, based on publicly available information

Xiulan Zheng

Department of Ultrasonography Harbin Medical University Cancer Hospital Harbin China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
XZXuefei Zhang
Xuefei Zhang
SSShiyao Sui
Shiyao Sui
LWLingling Wang
Lingling Wang
HLHaixia Li
Haixia Li
LZLei Zhang
Lei Zhang
XZXiulan Zheng
Xiulan Zheng

13 October 2015 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
JTJiebing Tang
Jiebing Tang
YCYuanyuan Chen
Yuanyuan Chen
RCRongjun Cui
Rongjun Cui
DLDong Li
Dong Li
LXLijie Xiao
Lijie Xiao
XZXiulan Zheng
Xiulan Zheng
Hypoxia is a common phenomenon in prostate cancer, which leads to cell proliferation and tumor growth. Fractalkine (FKN) is a membrane‑bound chemokine, which is implicated in the progression of human prostate cancer and skeletal metastasis. However, the association between FKN and hypoxia‑induced prostate cancer cell proliferation remains to be elucidated. The present study demonstrated that hypoxia induced the expression and secretion of FKN in the DU145 prostate cancer cell line. Furthermore, inhibiting the activity of FKN with the anti‑FKN FKN‑specific antibody markedly inhibited hypoxia‑induced DU145 cell proliferation. Under normoxic conditions, DU145 cell proliferation markedly increased following exogenous administration of human recombinant FKN protein, and the increase was significantly alleviated by anti‑FKN, indicating the importance of FKN in DU145 cell proliferation. In addition, subsequent determination of cell cycle distribution and expression levels of two core cell cycle regulators, cyclin E and cyclin‑dependent kinase (CDK)2, suggested that FKN promoted the G1/S phase transition by upregulating the expression levels of cyclin E and CDK2. The results of the present study demonstrated that hypoxia led to the upregulation of the secretion and expression of FKN, which enhanced cell proliferation by promoting cell cycle progression in the prostate cancer cells. These findings provide evidence of a novel function for FKN, and suggest that FKN may serve as a potential target for treating androgen‑independent prostate cancer.